EMA Application withdrawn: Aduhelm (aducanumab) — Biogen Netherlands B.V.

View source ↗

Summary

EMA withdrew the application for Aduhelm (aducanumab) by Biogen Netherlands B.V. for Alzheimer’s disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Aduhelm (aducanumab)

Snippet

Status: Application withdrawn. Therapeutic area: Alzheimer Disease. MAH: Biogen Netherlands B.V.